Page 21 - Kirin Holdings Case Study

Creating Shared Value

By 2019 the Kirin Group had developed a unique business

portfolio composed of three core businesses—alcoholic

beverages, non-alcoholic beverages, and pharmaceuticals

and bio-chemicals utilizing the organizational capabilities
and resources accumulated in the existing core businesses

to foster new businesses. (See Diagram 12).

In the food & beverages domain, Kirin Group aimed to

contribute to society by developing products with new value
by advancing technology throughout the supply chain to

improve product quality and business profitability. In the

pharmaceuticals domain, it aimed to create new medical
value by leveraging its leading biotechnologies and

advancing R&D mainly in the four areas of nephrology,

oncology, immunology/allergy, and the central nervous
system. The mission of these new businesses bridging

pharmaceuticals and Food & Beverages segment was to

provide new value in the four areas of lifestyle support,

immune system, brain function, and plant-based “smart
cells.” The new segment’s consumer targets fell into the

categories of individuals with specific needs and preventive

healthcare. Kirin Group would also support specific needs

by applying the high-function materials developed in its
food & beverages business to address unmet medical needs

(See Diagram 5 and 6).